HealthEquity, Inc. (NASDAQ:HQY) Director Frank Medici sold 7,900 shares of the firm’s stock in a transaction on Tuesday, October 24th. The shares were sold at an average price of $51.11, for a total value of $403,769.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Frank Medici also recently made the following trade(s):

  • On Monday, October 9th, Frank Medici sold 316,644 shares of HealthEquity stock. The shares were sold at an average price of $51.96, for a total value of $16,452,822.24.

HealthEquity, Inc. (NASDAQ HQY) traded up 1.19% during trading on Thursday, reaching $49.18. The company had a trading volume of 325,150 shares. The firm’s 50 day moving average price is $48.83 and its 200 day moving average price is $47.34. HealthEquity, Inc. has a 12-month low of $30.34 and a 12-month high of $54.95. The firm has a market capitalization of $2.97 billion, a PE ratio of 72.97 and a beta of 1.80.

HealthEquity (NASDAQ:HQY) last issued its earnings results on Tuesday, September 5th. The company reported $0.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.14 by $0.13. HealthEquity had a return on equity of 13.93% and a net margin of 20.27%. The business had revenue of $56.90 million during the quarter, compared to analysts’ expectations of $55.66 million. During the same quarter in the prior year, the firm earned $0.16 EPS. The business’s revenue for the quarter was up 28.7% compared to the same quarter last year. Analysts anticipate that HealthEquity, Inc. will post $0.71 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This news story was posted by American Banking News and is owned by of American Banking News. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright & trademark laws. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/10/26/insider-selling-healthequity-inc-hqy-director-sells-7900-shares-of-stock.html.

Institutional investors and hedge funds have recently modified their holdings of the business. Fifth Third Bancorp increased its holdings in HealthEquity by 382.8% in the 1st quarter. Fifth Third Bancorp now owns 2,414 shares of the company’s stock worth $102,000 after purchasing an additional 1,914 shares in the last quarter. Oppenheimer Asset Management Inc. acquired a new position in HealthEquity in the 1st quarter worth about $106,000. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in HealthEquity by 105.8% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,544 shares of the company’s stock worth $127,000 after purchasing an additional 1,308 shares in the last quarter. Riverhead Capital Management LLC increased its holdings in HealthEquity by 75.3% in the 2nd quarter. Riverhead Capital Management LLC now owns 2,629 shares of the company’s stock worth $131,000 after purchasing an additional 1,129 shares in the last quarter. Finally, Exane Derivatives acquired a new position in HealthEquity in the 2nd quarter worth about $132,000. 90.95% of the stock is owned by institutional investors and hedge funds.

A number of analysts have recently weighed in on the company. BidaskClub lowered HealthEquity from a “hold” rating to a “sell” rating in a research note on Wednesday, October 18th. TheStreet upgraded HealthEquity from a “c” rating to a “b” rating in a research note on Monday, July 31st. Zacks Investment Research lowered HealthEquity from a “buy” rating to a “hold” rating in a research note on Friday, August 4th. Robert W. Baird restated a “hold” rating on shares of HealthEquity in a research note on Thursday, September 21st. Finally, Oppenheimer Holdings, Inc. restated a “buy” rating and issued a $61.00 target price on shares of HealthEquity in a research note on Wednesday, September 6th. One analyst has rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $57.17.

About HealthEquity

HealthEquity, Inc provides a range of solutions for managing healthcare accounts (Health Savings Accounts (HSAs), Health Reimbursement Arrangements (HRAs) and Flexible Spending Accounts (FSAs)) for health plans, insurance companies and third-party administrators. The Company is engaged in technology-enabled services platforms that allow consumers to make healthcare saving and spending decisions.

Insider Buying and Selling by Quarter for HealthEquity (NASDAQ:HQY)

Receive News & Ratings for HealthEquity Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HealthEquity Inc. and related companies with MarketBeat.com's FREE daily email newsletter.